

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

14<sup>th</sup> February, 2018

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

**Kind Attn: General Manager-DCS**

Scrip Code: 533543

**Kind Attn: Head- Listing**

Symbol: BROOKS

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 3<sup>rd</sup> quarter ended 31<sup>st</sup> December, 2017. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



502, Kanakia  
Atrium-2, Andheri (E),  
Mumbai-400093

**(Jyoti Sancheti)**

**Company Secretary cum Compliance Officer**

Encl.: As Stated Above

**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net

Website: www.brookslabs.net

Tel No : +91 1795 654001/02/03,


Fax No :+91 1795 236939

**Statement of Unaudited Financial Results for the Quarter and nine months ended 31st December, 2017**

(Rs. In Lakhs)

No	Particulars	Quarter Ended			Nine Month Ended	
		31-Dec-17	30-Sep-17	31-Dec-16	31-Dec-17	31-Dec-16
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited
1	<b>Income</b>					
	(a) Revenue from operations	2,087.50	1,316.51	1,647.48	4,238.81	4,856.34
	(b) Other Income	2.27	6.42	3.95	12.17	7.35
	<b>Total income</b>	<b>2,089.77</b>	<b>1,322.93</b>	<b>1,651.43</b>	<b>4,250.98</b>	<b>4,863.69</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	1,516.16	917.35	1,004.50	3,027.02	2,690.52
	(b) Change in inventories of finished goods, work-in-progress and stock-in-trade	14.57	62.89	(87.94)	(21.08)	(61.97)
	(c) Excise Duty on Sales	-	-	239.59	119.27	534.62
	(d) Employees benefits expenses	305.68	288.96	202.57	849.60	586.93
	(e) Finance Costs	71.38	54.69	25.34	171.60	68.41
	(f) Depreciation and amortization expenses	164.32	162.05	33.51	483.13	97.39
	(g) Other expenses	351.05	317.83	167.28	978.99	531.92
	<b>Total Expenses</b>	<b>2,423.16</b>	<b>1,803.77</b>	<b>1,584.85</b>	<b>5,608.53</b>	<b>4,447.82</b>
3	<b>Profit/(Loss) before exceptional items and tax</b>	<b>(333.39)</b>	<b>(480.84)</b>	<b>66.58</b>	<b>(1,357.55)</b>	<b>415.87</b>
4	Exceptional Items	-	-	-	-	-
5	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>(333.39)</b>	<b>(480.84)</b>	<b>66.58</b>	<b>(1,357.55)</b>	<b>415.87</b>
6	<b>Tax Expense:</b>					
	Current Tax	-	-	14.61	-	87.89
	MAT credit (Entitlement)/Utilised	-	-	39.10	-	39.10
	Deferred Tax Liability / (Assets)	(71.13)	(178.67)	(35.03)	(205.44)	(0.19)
	Short income tax provision for earlier years	(0)	2.95	-	2.95	4.32
7	<b>Net Profit/(loss) after tax</b>	<b>(262.26)</b>	<b>(305.12)</b>	<b>47.90</b>	<b>(1,155.06)</b>	<b>284.75</b>
8	<b>Other Comprehensive Income</b>					
	<b>Items That will not be reclassified into Profit or loss</b>					
	Actuarial loss on Defined Benefit plans (net of tax).	0.01	0.01	0.54	0.03	1.61
9	<b>Total Comprehensive income for the period (After tax)</b>	<b>(262.25)</b>	<b>(305.11)</b>	<b>48.44</b>	<b>(1,155.03)</b>	<b>286.36</b>
10	<b>Paid - up equity share capital of Rs.10 each</b>	<b>1,618.64</b>	<b>1,618.64</b>	<b>1,618.64</b>	<b>1,618.64</b>	<b>1,618.64</b>
11	<b>Earnings per share (of Rs. 10/- each)</b>					
	(not annualised)					
	(a) Basic	(1.62)	(1.89)	0.30	(7.14)	1.76
	(b) Diluted	(1.62)	(1.89)	0.30	(7.14)	1.76

For Brooks Laboratories Ltd.

  
Chairman

**Notes:**

- 1 The above unaudited financial results of the Company for the quarter/ nine months ended 31st December, 2017 have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on 14th February, 2018.
- 2 The Ind-AS compliant corresponding figures for the quarter and nine months ended 31st December 2016 have not been subjected to review or audit. However, the Company's management has exercised due diligence to ensure that the financial results provide fair view of its affairs. The statement does not include Ind-AS compliant results for the previous year ended March 31, 2017 as it is not mandatory as per SEBI Circular dated July 05, 2016.
- 3 The Company adopted Indian Accounting Standards ("Ind-AS") and accordingly the financial results of all periods presented have been prepared in accordance with the recognition and measurement principles laid down in the Ind-AS-34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. The date of transition to Ind AS is 1st April, 2016. There is a possibility that these quarterly financial results may require adjustment before constituting the final Ind-AS financial statements as of and for the year ending 31st March, 2018 due to changes in financial reporting requirement arising from new or revised standards or interpretations issued by Ministry of Corporate Affairs to changes in the use of one or more optional exemptions from full retrospective application of certain Ind-AS permitted under Ind-AS 101.
- 4 The Statutory Auditors have carried out Limited Review of the Financial Results of the Company for the Quarter/ Nine months ended December 31, 2017.
- 5 Consequent to the introduction of Goods and Services Tax (GST) with effect from July 1, 2017, Central Excise Duty, Value Added Tax (VAT), etc, have been replaced by GST. In accordance with Ind AS-18 "Revenue" and Schedule-III of Companies Act, 2013, GST is not included in total income from operation for quarter ended post July 1st, 2017. However, for the quarter ended June 30th, 2017 and earlier comparative periods, excise duty is included in revenue from operations, hence not comparable.
- 6 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS – 108 in this regard are not applicable.
- 7 Reconciliation of Net Profit and Total Comprehensive Income on account of transition from the previous Indian GAAP to Ind-AS for the quarter and nine months ended December 31, 2016 is as under:

(Rs. In Lakhs)

Sr. No.	Particular	For the Quarter Ended December 31, 2016	For the Nine months ended December 31, 2016
	<b>Net Profit as per Indian GAAP</b>	<b>47.63</b>	<b>284.07</b>
	Benefit / (Charge)		
I	Actuarial Loss on Defined Benefit Plans reclassified to other comprehensive Income	(0.80)	(2.41)
II	Provision for Effective credit loss	(4.30)	(12.97)
III	Deferred tax impacts on Ind AS Adjustments	5.37	16.07
	<b>Net Profit for Quarter ( as per Ind-AS)</b>	<b>47.90</b>	<b>284.75</b>
	<b>Other Comprehensive Income</b>		
	Actuarial Loss on Defined Benefit Plans (net of tax)	0.54	1.61
	<b>Total Comprehensive Income</b>	<b>48.44</b>	<b>286.36</b>

- 8 Comparative financial information of the previous quarter and nine months have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.

Place : Mumbai

Date : 14th February, 2018



For and on Behalf of Board

Chairman

DIN No. 01998361